Cumulative subject index for volumes 29–31

GYNECOLOGICONCOLOGY31, 483-502 (1988)

Cumulative Subject Index 1 for Volumes 29-31

Abdominopelvis irradiation following reexploration for ovarian carcinoma, evaluation, 31, 396 salvage radiotherapy after chemotherapy for ovarian carcinoma, evaluation, 30, 15 Abortion repeated spontaneous, association with increased frequency of complete hydatidiform mole, 31. 310 Abstracts Society of Gynecologic Oncologists. Nineteenth Annual Meeting, February 1988. 29, 127 %-Acid glycoprotein serum levels, analysis in epithelial ovarian cancer patients receiving chemotherapy, 29, 3O5 Acquired immune deficiency syndrome positive status, association with positive Papanicolaou screening: identification of highrisk population, 31, 184; discussion. 31. 189 Adenocarcinoma cervix epidemiology, 31, 25 prognostic features, analysis. 31, 137; discussion, 31, 149; response, 31, 152 endometrium associated epithelial mucin secretion pattern, 30, 274 associated sclerosing stromal tumor of ovary, case report, 29, 392 cardiac metastasis malignant pericardial effusion, case report. 29, 234 to right ventricle, case report, 29, 231 cell line HEC-IA. cytogenetics and implications, 31. 217 c~-fetoprotein-produeing, case report, 29, 370 sequential cyclical hormonal therapy, efficacy

and correlation with steroid receptor status, 31, 327 ovary advanced, combination and single-agent chemosensitivity prediction in, concordance with murine subrenal capsule xenograft assay, 30, 416 associated CA125 in tumor tissue and serum, determination, 30, 342 invasive, monitoring by serum CA125 and lipid-associated sialic acid levels, comparison, 30, 98 peritoneal papillary, clinical features and treatment results, 31, 315 primary, localized to fallopian tubes, report on 33 cases, 30, 183 vaginal clear cell, Stage II, categorization into substages, evaluation, 31, 56 vulva, clear cell, arising in endometriosis, case report, 29, 385 Adenosarcoma cervix, miJllerian, case report, 31, 445 uterus, miillerian, case report and literature review, 30, 291 Administration route continuous infusion versus intermittent bolus fluoropyrimidines, as salvage therapy in advanced ovarian carcinoma, analysis, 29. 348 intravenous and intraperitoneal, cisplatin in treatment of microscopic ovarian cancer, comparison in murine model, 31, 50 Adnexa associated tumors in advanced ovarian carcinomas, epidermal growth factor receptors in, occurrence and prognostic value, 29, 147 Adriamycin, see Doxorubicin Age role in breast cancer detection: relationship to significance of physical exam and mam-

L Boldface numbers indicate appropriate volume; lightface numbers indicate pagination. 483 0090-8258/88 $1.50 Copyright © 1988 by Academic Press, Inc. All rights of reproduction in any form reserved.

484

SUBJECT INDEX

mography findings, 31, 166; discussion, 31, 173; response, 31, 175 under 20, associated patterns in molar pregnancy, 30, 196 under 35, associated recurrent and persistent squamous cell cervical carcinoma with poor prognosis, evaluation, 30, 163 35 or under, carcinoma of cervix, comparison of treatment modality and survival, 31,430 65 or older, Wertheim hysterectomy for primary treatment of cervical carcinoma, evaluation, 31, 227 AIDS, s e e Acquired immune deficiency syndrome Alkaline phosphatase serum levels, analysis in pure ovarian dysgerminoma, 30, 44 Altretamine as first-line chemotherapy in treatment of advanced or recurrent endometrial carcinoma: phase II trial of Gynecologic Oncology Group, 31, 435 Amylase producing CAl9-9-positive ovarian mucinous cystadenocarcinoma, immunohistochemical and immunoelectron microscopic study, 30, 372 Anastomosis low rectal, at time of pelvic exenteration for cervical carcinoma, evaluation, 31, 262 Angiogenesis associated activity of gynecologic tumor cell lines on chorioallantoic membrane (chicken embryo), 29, 87 Announcements Advances in Gynecologic Oncology, Boston, Massachusetts, September 1988, 30, 435 Chemotherapy Foundation Symposium VIII: Innovative Cancer Chemotherapy for Tomorrow, New York, November 1988, 30, 435 Postgraduate Course in Gynecologic and Ob~stetric Pathology with Clinical Correlation, Boston, Massachusetts, April 1988, 29, 126; 31, 479 Postgraduate Course in Gynecologic Pathology, Washington, D.C., November 1988, 31,248 Antibodies monoclonal, to lymphocyte markers, crossreactivity with trophoblast cells of normal placenta, hydatidiform mole, and gestational choriocarcinoma, 29, 94 Antigens Ca-I, distribution in neoplastic cervical lesions, comparison with cervical carcinoma antigen, 30, 63

CA15-3, as tumor marker in gynecological malignancies, analysis, 30, 265 CA19-9, positive amylase-producing ovarian mucinous cystadenocarcinoma, immunohistochemical and immunoelectron microscopic study, 30, 372 CA125, s e e Cancer antigen 125 carcinoembryonic, s e e Carcinoembryonic antigen cervical carcinoma, distribution in neoplastic cervical lesions and comparison with other tumor markers, 30, 63 epithelial membrane, distribution in neoplastic cervical lesions, comparison with cervical carcinoma antigen, 30, 63 herpes simplex virus and human papillomavirus, search for presence in specimens of Paget's disease of vulva, 31, 384 lymphocyte, monoclonal antibodies to, crossreactivity with trophoblast cells of normal placenta, hydatidiform mole, and gestational choriocarcinoma, 29, 94 tissue polypeptide, with CA125 and other tumor markers, combination assay in serum for ovarian cancer, 29, 66 Ataxia-telangiectasia association with endodermal sinus tumor of ovary, case report, 29, 240 ATP (adenosine 5'-triphosphate) bioluminescence assay, application in human tumor chemosensitivity testing, 31, 191

Bacillus Calmette-Gurrin disseminated infection, rapid onset after chemoimmnnotherapy for ovarian carcinoma, 31, 321 Basal cell carcinoma vulva, with inguinal lymph node metastases, case report, 29, 113 Bioluminescence assay ATP, application in human tumor chemosensitivity testing, 31, 191 Bleomycin with mitomycin, vincristine, and cisplatin, phase II trial as neoadjuvant therapy in high-risk cervical carcinoma, 30, 1 with vinblastine and c i s - p l a t i n u m , in preoperative adjuvant chemotherapy in treatment of cervical cancer Stages Ib, IIa, and lib with bulky tumor, 29, 321 Book reviews Advances in Radiation Biology, Volume 12: Relative Radiation Sensitivities of Human

SUBJECT INDEX Organ Systems. J. T. Lett and K. I. Altman (Eds.), 1987, 29, 124 CA125: A New Tool in the Diagnosis and Management of Ovarian Tumors. G. B. Massi (Ed.), 1987, 31, 478 Modern Brachytherapy. B. Pierquin et al. (Eds.), 1987, 29, 124 Brain metastatic gestational choriocarcinoma late recurrence, case report, 31, 467 with primary neurological presentation, case report, 29, 361 Breast cancer detection, age-related significance of physical exam and mammography findings, 31,166; discussion, 31, 173; response, 31, 175 G CA125, see Cancer antigen 125 Cancer, see also specific type breast, detection: age-related significance of physical exam and mammography findings, 31, 166: discussion, 31, 173; response, 31, 175 cervix in Nijmegen region, The Netherlands population screening, 1976-1985, 30, 388 survival, 1970-1985, evaluation, 30, 51 recurrent, role of anterior pelvic exenteration in treatment, 31,205; discussion, 31,214; response, 31, 216 treatment with para-aortic node irradiation, evaluation, 31, 371 gynecologic radical pelvic surgery in, associated neuropathies, case reports, 31, 462 urinary gonadotropin fragments as markers initial serial studies, 31, 91 sensitivity and specificity, comparison with other markers, 31, 82; discussion, 31, 101 ovary advanced, various microscopical features of second-look specimen, clinical relevance, 29, 58 epithelial advanced, methotrexate-thio-TEPA-vincristine chemotherapy regime for, case studies over 10-year period, 31, 285 routine second-look laparotomy for, evaluation of justification, 31, 249 microscopic, treatment with iv and ip cisplatin, comparison in murine model, 31, 50

485

second-look laparotomy with preoperative computed tomography, comparison of findings, 29, 37 tumor markers CA125, tissue polypeptide antigen, immunosuppressive acid protein, carcinoembryonic antigen, and ferritin in serum, combination assay, 29, 66 tumor mass and clinical outcome, assessment with serial D-dimer levels, 29, 188 vagina, nonsquamous, clinical characteristics and treatment, 29, 309 Cancer antigen 125 determination in tumor tissue and serum in ovarian adenocarcinoma patients, 30, 342 and lipid-associated sialic acid, serum levels in monitoring patients with invasive ovarian adenocarcinoma, comparison, 30, 98 and other tumor markers, combination assay in serum for ovarian cancer, 29, 66 plasma, as marker for gynecologic cancers, comparison with urinary gonadotropin fragments correlation with changing clinical status, 31, 91 sensitivity and specificity, 31, 82; discussion, 31, 101 role in management of ovarian epithelial carcinomas, 30, 26 serum half-life during induction chemotherapy for ovarian cancer, prognostic value, 30, 307 serum levels elevated, association with epithelial ovarian cancer metastatic to retroperitoneal lymph nodes, case report, 29, 356; letter to editor, 31, 365; reply, 31, 366 preoperative, in early-stage ovarian carcinoma patients, initial analysis, 30, 7 Carcinoembryonic antigen detection in primary and metastatic ovarian tumors, 30, 407 distribution in neoplastic cervical lesions, comparison with cervical carcinoma antigen, 30, 63 and other tumor markers, combination assay in serum for ovarian cancer, 29, 66 Carcinoid cervix, case report: natural history and implications for therapy, 30, 114 Carcinoma, see also specific type cervix advanced, modified VBP neoadjuvant chemotherapy, phase II trial results, 31, 256 associated invasion of uterine body, analysis of surgical specimens, 30, 173

486

SUBJECT INDEX

associated type of human papillomavirus, prognostic significance, 29, 267 cell lines Caski, HeLa, and ME-180, in vitro response to antiestrogen tamoxifen, 30, 228 diagnosed in second trimester of pregnancy, management problems, 30, 120 endometrial extension, prognostic significance, 31, 301 in geriatric population, Wertheim hysterectomy for primary treatment, evaluation, 31, 227 high-risk, phase II trial of mitomycin, vincristine, Neomycin, and cisplatin as neoadjuvant therapy, 30, I identification of transferrin receptors, 31, 292 in patients 35 years or younger, comparison of treatment modality and survival, 31,430 presentation with vagino-peritoneal fistula, case report, 31, 352 primary, computerized tomography in presurgical evaluation, predictive value, 30, 209 radiotherapy, bladder and rectal complications, 29, 1 recurrent and metastatic, treatment with cisplatin, doxorubicin, and cyclophosphamide, 29, 32 or persistent, low rectal resection and anastomosis at time of pelvic exenteration, evaluation, 31, 262 after radical hysterectomy, clinical nature, 30, 381 squamous cell immune function in patients as indicator of clinical status, multiparameter analysis, 31, 409 metastatic, management of associated malignant pericardial effusion, case report, 31, 338 metastatic and recurrent, treatment with bolus cis-platinum and 5-fluorouracil continuous infusion, evaluation, 29, 76 recurrent and persistent in women under age 35, evaluation, 30, 163 Stage IB, with lymph node metastases, clinical factors affecting survival, review, 31, 389 Stages IB, IIA, and liB, with bulky tumor, preoperative adjuvant chemotherapy, 29, 321 endometrium advanced or recurrent, treatment with hexamethylmelamine as first-line chemotherapy: phase II trial of Gynecologic Oncology

Group, 31,435 cell lines, /'n vitro growth regulation by tamoxifen and medroxyprogesterone acetate, 30, 239 identification of transferrin receptors, 31, 292 lymphography in initial evaluation, applicability, 31, 276 peritoneal cytology in, prognostic significance, 30, 76 primary squamous cell, case report, 3I, 454 survival as function of cytosolic estrogen and progestin receptor levels, analysis, 31, 65; discussion, 31, 78; response, 31, 81 ovary abdominopelvic irradiation following reexploration, evaluation, 31, 396 adenosquamous, involvement of spleen, case report, 30, 143 advanced associated adnexal tumors, epidermal growth factor receptors in, occurrence and prognostic value, 29, 147 associated central nervous system lesions, evaluation, 30, 87 with central nervous system relapse, evaluation, 30, 398 cisplatin and VP-16-213 treatment, evaluation, 30, 159 clinical variables associated with prognosis, 30, 347 continuous-infusion fluoropyrimidines as salvage therapy, evaluation, 29, 348 dubulking surgery with Cavitron ultrasonic surgical aspirator, preliminary report, 31, 223 interval reassessment operations during chemotherapy, 30, 359 prognostic DNA flow cytometry and morphometry for, analysis, 29, 176 survival after chemotherapy, relationship to dose level and treatment intensity, 31, 233; discussion, 31, 246 treatment with viral oncolysates, evaluation, 29, 337 all histological types, management, role of CA125, 30, 26 anaplastic cell line HTBOA, establishment and characterization, 30, 35 associated malignant pericardial effusion, cure by systemic chemotherapy, case report, 30, 298 chemoimmunotherapy including bacillus Calmette-Gudrin, subsequent disseminated granulomatous disease, 31, 321

SUBJECT INDEX determinants of survival after whole-abdomen irradiation, 30, 201 early-stage, preoperative serum CA125 levels, initial analysis, 30, 7 established human cell lines, plasminogen activator secretion in vitro, 31, 103 lymphoceles development after second-look laparotomy, case report, 29, 382 metastatic to retroperitoneal lymph nodes, association with elevated serum CA125, case report, 29, 356; letter to editor, 31, 365; reply, 31, 366 minimal residual after surgical resection and maximal first-line chemotherapy, wholeabdomen radiation for, 29, 168 patients with multiple previous intraabdominal procedures for, complications of Tenckhoff catheter implantation, 29, 43 persistent, salvage treatment following chemotherapy by hyperfractionation of whole-abdominal radiotherapy, 31, 122; discussion, 31, 135 plasma estradiol levels, analysis, 30, 313 positive second-look laparotomy, evaluation of subsequent treatment and survival. 31, 9; discussion, 31, 22; response, 31, 24 prechemotherapy CA125 serum half-life during induction therapy, prognostic value, 30, 307 salvage radiotherapy following chemotherapy, 30, 15; erratum, 31, 369 serum a~-acid glycoprotein levels in patients receiving chemotherapy, 29, 305 small-cell, aggressive epithelial cancer in young patients, case report, 29, 365 squamous arising in dermoid cysts and associated with hypercalcemia, clinicopathologic case studies, 29, 222 pure primary, case report, 29, 257 Stage II, pelvic irradiation, 20-year review, 29, 26 Stages III and IV negative second-look laparotomy, subsequent recurrence, 29. 274 treatment with adriamycin plus cisplatin, 29, 208 whole-abdominal radiotherapy following cytoreductive surgery and chemotherapy, evaluation, 31, 113; discussion, 31, 121 vulva basal cell, with inguinal lymph node metastases, case report, 29, 113 depth of invasion, comparative morphometric

487

study, 29, 12 early, prognostic factors, 31, 43 electrosurgical operation with postoperative irradiation of inguinal lymph nodes, analysis, 29, 158 invasive, unrecognized in vulvar intraepithelial neoplasia, evaluation, 31, 154; discussion, 31, 163; response, 31, 165 neuroendocrine Merkel cell, case report, 29, 105 Paget's disease, specimen analysis for herpes simplex virus antigens and human papillomavirus antigen and DNA, 31, 384 verrucous, ease report and literature review, 30, 427 Catheters Tenckhoff, see Tenckhoff catheter Cavitron ultrasonic surgical aspirator application in debulking surgery for ovarian cancer, preliminary report, 31, 223 Cell lines cervical carcinoma, Caski, HeLa, and ME- 180, in vitro response to antiestrogen tamoxifen, 30, 228 endometrial carcinoma HEC-IA, cytogenetics and implications, 31, 217 HEC-1, KLE, RL95-2, and UM-EC-1, in vitro growth regulation by tamoxifen and medroxyprogesterone acetate, 30, 239 gynecologic tumors, on chorioallantoic membrane, tumor angiogenic activity (chicken embryo), 29, 87 ovarian carcinoma HTBOA, anaplastic, establishment and characterization, 30, 35 human, plasminogen activator secretion in vitro, 31, 103 MDAH 2774 and CaOV3, derived viral oncolysates, in treatment of advanced ovarian cancer, 29, 337 NIHL:OVCAR-3, chemosensitivity in ATPbioluminescence assay, 31, 191 ovarian endodermal sinus tumor, producing specific type of c~-fetoprotein, establishment and characterization, 25,281; letter to editor, 31, 367 Cellulitis leg, recurrent acute, occurrence in patients after radical vulvectomy, 29, 50 Central nervous system involvement in relapse of advanced ovarian carcinoma, evaluation, 30, 398 lesions, association with advanced ovarian cancer, evaluation, 30, 87

488

SUBJECT INDEX

Cervical adenocarcinoma epidemiology, 31, 25 prognostic features, analysis, 31, 137; discussion, 31, 149; response, 31, 152 Cervical adenosarcoma mrallerian, management, case report, 31,445 Cervical cancer in Nijmegen region, The Netherlands population screening, 1976-1985, 30, 388 survival, 1970-1985, evaluation, 30, 51 recurrent, role of anterior pelvic exenteration in treatment, 31, 205; discussion, 31,214: response, 31, 216 treatment with para-aortic node irradiation, evaluation, 31, 371 Cervical carcinoma advanced, modified VBP neoadjuvant chemotherapy, phase lI trial results, 31, 256 associated invasion of uterine body, analysis of surgical specimens, 30, 173 associated type of human papillomavirus, prognostic significance, 29, 267 cell lines Caski, HeLa, and ME-180, in vitro response to antiestrogen tamoxifen, 30, 228 diagnosed in second trimester of pregnancy, management problems, 30, 120 endometrial extension, prognostic significance, 31,301 in geriatric population, Wertheim hysterectomy for primary treatment, evaluation, 31,227 high-risk, phase 1I trial of mitomycin, vincristine, Neomycin, and cisplatin as neoadjuvant therapy, 30, 1 identification of transferrin receptors. 31, 292 in patients 35 years or younger, comparison of treatment modality and survival, 31, 430 presentation with vagino-peritoneal fistula, case report, 31, 352 primary, computerized tomography in presurgical evaluation, predictive value, 30, 209 radiotherapy, bladder and rectal complications, 29, 1 recurrent and metastatic, treatment with cisplatin, doxorubicin, and cyclophosphamide, 29, 32 or persistent, low rectal resection and anastomosis at time of pelvic exenteration for, evaluation, 31, 262 after radical hysterectomy, clinical nature, 30, 381 specific antigen, distribution in neoplastic cervical lesions and comparison with other

tumor markers, 30, 63 squamous cell immune function in patients as indicator of clinical status, multiparameter analysis, 31, 409 metastatic management of associated malignant pericardial effusion, case report, 31, 338 and recurrent, treatment with bolus cisplatinum and 5-fluorouracil continnous infusion, evaluation, 29, 76 recurrent and persistent in women under age 35, evaluation, 30, 163 Stage IB, with lymph node metastases, clinical factors affecting survival, review, 31, 389 Stages IB, IIA, and liB, with bulky tumor, preoperative adjuvant chemotherapy, 29, 321 Cervical lymphoma primary aneuploid, case report, 30, 302 Cervical melanosis case report, 29, I01 Cervical neopJasia distribution of cervical carcinoma antigen and comparison with other tumor markers, 30, 63 intraepithelial and invasive, risk, relationship to dietary vitamin A, 30, 187 treatment with cryosurgery, retrospective evaluation, 30, 21 Cervix carcinoid tumor, case report: natural history and implications for therapy, 30, 114 identification of transferrin receptors, 31, 292 intraepithelial neoplasia, differentiation from human papillomavirus, role of colposcopy, 27, 197; letter to editor, 29, 120: reply, 29, 121 premalignant lesions, screening for human papillomavirus type 16 DNA by sandwich and in situ hybridization techniques, comparison, 30, 251 sarcoma botryoides in young women, clinicopathological study of 13 cases, 29, 290 tumor, presentation of Burkitt's-fike lymphoma as, case report, 30, 131 Chemoimmunotherapy with bacillus Calmette-Gu6rin for ovarian carcinoma, subsequent disseminated granulomatous disease, 31, 321 Chemosensitivity combination and single-agent, prediction in ovarian carcinoma by murine subrenal

SUBJECT INDEX capsule xenograft assay, concordance with therapy results, 30, 416 human tumors, application of ATP-bioluminescence assay, 31, 191 Chemotherapy adriamycin plus cisplatin, in treatment of Stage III and IV epithelial ovarian carcinoma, 29, 208 for advanced ovarian carcinoma, interval reassessment operations during, evaluation, 30, 359 cisplatin based VAB, primary therapy in nondysgerminomatous germ cell malignancies of ovary, role of second-look laparotomy, 31, 268 bolus, and 5-fluorouracil continuous infusion. for metastatic and recurrent squamous cell carcinoma of cervix, evaluation, 29, 76 for microscopic ovarian cancer, comparison of ip and iv treatment in routine model, 31, 50 and VP-16-213, in treatment of advanced ovarian carcinoma, evaluation, 30, 159 cisplatin, doxorubicin, and cyclophosphamide for advanced epithelial ovarian carcinoma, relationship of survival to dose level and treatment intensity, 31, 233; discussion, 31, 246 in ovarian carcinoma, tumor sensitivity to, correlation with combination and singleagent chemosensitivity prediction by routine subrenal capsule xenograft assay, 30, 416 systemic, in treatment of malignant pericardial effusion in ovarian carcinoma, case report, 30, 298 in treatment of recurrent and metastatic cervical cancer, 29, 32 and cytoreductive surgery, in ovarian carcinoma, evaluation of subsequent whole-abdominal radiotherapy, 31, 113; discussion, 31, 121 EMA/CO regimen, in high-risk gestational trophoblastic tumor, 31, 439 first-line hexamethylmelamine in treatment of advanced or recurrent endometrial carcinoma: phase II trial of Gynecologic Oncology Group, 31, 435 maximal, and surgical resection, subsequent minimal residual epithelial ovarian carcinoma, treatment with whole-abdomen radiation, 29, 168

489

induction, for ovarian cancer, prognostic value of CA125 serum half-life during, 30, 307 methotrexate-thio-TEPA-vincristine, forovarJan cancer, case studies over 10-year period, 31, 285 mitomycin, vincristine, bleomycin, and cisplatin, as neoadjuvant therapy in high-risk cervical carcinoma, phase II trial, 30, 1 neoadjuvant, modified VBP, in cervical carcinoma, phase II trial results, 31, 256 in ovarian carcinoma salvage treatment for subsequent persistent disease by hyperfvactionation of whole-abdominal radiotherapy, 31, 122; discussion, 31, 135 serum a~-acid glycoprotein levels in recipient patients, 29, 305 subsequent salvage radiotherapy, 30, 15; err a t u m , 31, 369 in treatment of immature teratoma of ovary, results, 30, 321 VAC, adjuvant, for grade 3 immature ovarian teratoma, normal pregnancy and delivery two years after, 29, 245 vinblastine, bleomycin, and c/s-platinum, preoperative adjuvant, in treatment of cervical cancer Stages IB, IIA, and lIB with bulky tumor, 29, 321 Chorioallantois gynecologic tumor cell lines on, tumor angiogenic activity (chicken embryo), 29, 87 Choriocarcinoma gestational, s e e Gestational choriocarcinoma Cisplatin and adriamycin, in treatment of Stage lII and IV epithelial ovarian carcinoma, 29, 208 based VAB primary chemotherapy, in nondysgerminomatous germ cell malignancies of ovary, role of second-look laparotomy, 31, 268 bolus, and 5-fluorouracil continuous infusion, for metastatic and recurrent squamous cell carcinoma of cervix, evaluation, 29, 76 with cyclophosphamide and doxorubicin or alone, in combination and single-agent chemosensitivity prediction in ovarian carcinoma by routine subrenal capsule xenograft assay, 30, 416 as combination chemotherapy for ovarian carcinoma, relationship of survival to dose level and treatment intensity, 31,233; discussion, 31, 246 systemic, in treatment of malignant pericardial

490

SUBJECT INDEX

effusion in ovarian carcinoma, case report, 30, 298 in treatment of recurrent and metastatic cervical cancer, evaluation, 29. 32 induced hypomagnesemia with seizures, case report and literature review, 30, 104 iv and ip administration in treatment of microscopic ovarian cancer, comparison in murine model, 31, 50 with mitomycin, vincristine, and bleomycin, phase II trial as neoadjuvant therapy in high-risk cervical carcinoma, 30, 1 with vinblastine and bleomycin, in preoperative adjuvant chemotherapy in treatment of cervical cancer Stages IB. IIA, and IIB with bulky tumor, 29, 321 and VP-16-213, in treatment of advanced ovarian carcinoma, evaluation, 30, 159 Colposcopy role in differentiation of human papillomavirus from cervical intraepithelial neoplasia, 27, 197; letter to editor, 29, 120; reply, 29, 121 Computerized tomography preoperative, in ovarian cancer patients, comparison of findings with second-look laparotomy, 29, 37 in presurgical evaluation of primary carcinoma of cervix, predictive value, 30, 209 Cryosurgery for cervical intraepithelial neoplasia, retrospective evaluation, 30. 21 Cyclophosphamide with cisplatin and doxorubicin or alone, in combination and single-agent chemosensitivity prediction in ovarian carcinoma by murine subrenal capsule xenograft assay, 30. 416 as combination chemotherapy for ovarian carcinoma, relationship of survival to dose level and treatment intensity, 31,233; discussion, 31, 246 systemic, in treatment of malignant pericardial effusion in ovarian carcinoma, case report, 30, 298 in treatment of recurrent and metastatic cervical cancer, evaluation, 29, 32 Cystadenocarcinoma ovary, mucinous amylase-producing CAl9-9-positive. immunohistochemical and immunoelectron microscopic study, 30, 372 with low malignant potential, association with mature cystic teratoma, case report, 29, 250

paraovarian, with low malignant potential, case report, 30, 216 Cysts dermoid, s e e Dermoid cyst Cytogenetics endometrial adenocarcinoma cell line, implications, 31, 217 Cytology peritoneal, in endometrial carcinoma patients, prognostic significance, 30, 76

Delivery normal, after normal pregnancy, 2 years after adjuvant chemotherapy for grade 3 immature ovarian teratoma, 29, 245 Deoxyribose -5-fluoronracil, alone or in combination with other drugs, continuous infusion as salvage therapy in advanced ovarian carcinoma, 29, 348 Dermatofibrosarcoma protuberans vulva, case report, 30, 149 Dermoid cyst association with ovarian mucinous cystadenocarcinoma of low malignant potential, case report, 29, 250 ovarian, derived squamous carcinoma associated with hypercalcemia, clinicopathologic case studies, 29, 222 Diet vitamin A intake, relationship to risk of intraepithelial and invasive cervical neoplasia, 30, 187 DNA flow cytometry and morphometry, as prognostic indicators in advanced ovarian cancer, analysis, 29, 176 human papillomavirus detection in female genital tract, correlation with histology, 31. 176 search for presence in specimens of Paget's disease of vulva, 31, 384 type 16. in premalignant cervical lesions, screening by sandwich and bz situ hybridization techniques, comparison, 30, 251 Dosage and intensity, in ovarian carcinoma chemotherapy, relationship to survival, 31, 233; discussion, 31, 246 Doxorubicin with cisplatin and cyclophosphamide or alone, in combination and single-agent

SUBJECT INDEX chemosensitivity prediction in ovarian carcinoma by murine subrenal capsule xenograft assay, 30, 416 as combination chemotherapy for ovarian carcinoma, relationship of survival to dose level and treatment intensity, 31,233; discussion, 31, 246 systemic, in treatment of malignant pericardial effusion in ovarian carcinoma, case report, 30, 298 in treatment of recurrent and metastatic cervical cancer, evaluation, 29, 32 with cisplatin, in treatment of Stage III and 1V epithelial ovarian carcinoma, 29, 208 Dysgerminoma pure ovarian, serum lactic dehydrogenase, alkaline phosphatase, and human chorionic gonadotropin levels, analysis, 30, 44

Editorial A Statement on Behalf of St. Elsewhere: status of gynecologic oncology training and practice in U. S., 31, 474 Effusion malignant pericardial in endometrial adenocarcinoma, case report, 29, 234 in metastatic squamous cell carcinoma of cervix, management, case report, 31, 338 in ovarian carcinoma, cure by systemic chemotherapy, case report, 30, 298 Electrosurgery with postoperative irradiation of inguinal lymph nodes, in vulvar carcinoma, analysis, 29, 158 Embryo chorioallantoic membrane, gynecologic tumor cell lines on, tumor angiogenic activity (chicken), 29, 87 Endodermal sinus tumor ovarian, cell line producing specific type of c~fetoprotein, establishment and characterization, 25, 281; letter to editor, 31, 367 primary, arising in endometrium, successful treatment, case report, 31, 357 Endometrial adenocarcinoma associated epithelial mucin secretion pattern, analysis, 30, 274 associated sclerosing stromal tumor of ovary, case report, 29, 392 cardiac metastasis: malignant pericardial effusion, case report, 29, 234

491

cell line HEC-IA, cytogenetics and implications, 31, 217 c~-fetoprotein-producing, case report, 29, 370 right ventricular metastasis, case report, 29, 231 sequential cyclical hormonal therapy, efficacy and correlation with steroid receptor status, 31, 327 Endometrial carcinoma advanced or recurrent, treatment with hexamethylmelamine as first-line chemotherapy: phase II trial of Gynecologic Oncology Group, 31, 435 derived cell lines, in vitro growth regulation by tamoxifen and medroxyprogesterone acetate, 30, 239 identification of transferrin receptors, 31, 292 lymphography in initial evaluation, applicability, 31, 276 peritoneal cytology in, prognostic significance, 30, 76 primary squamous cell, case report, 31, 454 survival as function of cytosolic estrogen and progestin receptor levels, analysis, 31, 65; discussion, 31, 78: response, 31, 81 Endometriosis externa, with gliomatosis peritonei, case report, 29, 263 malignant extraovarian, case reports and literature review, 30, 123 vulva, clear cell adenocarcinoma arising in, case report, 29, 385 Endometrium identification of transferrin receptors, 31, 292 invasion of carcinoma of uterine cervix analysis of surgical specimens, 30, 173 prognostic significance, 31, 301 normal, hyperplastic, and adenocarcinomatous, epithelial mucin secretion pattern, 30,274 primary endodermal sinus tumor, successful treatment, case report, 31, 357 Epidemiology adenocarcinoma of cervix, evaluation, 31, 25 Epidermal growth factor receptors in adnexal tumors in advanced ovarian carcinomas, occurrence and prognostic value, 29, 147 Estradiol plasma levels, analysis in epithelial ovarian carcinoma patients, 30, 313 Etoposide with cisplatin, in treatment of advanced ovarian carcinoma, evaluation, 30, 159 Exenteration pelvic

492

SUBJECT INDEX anterior, role in treatment of recurrent cervical cancer, 31, 205; discussion, 31, 214; response, 31, 216 total, with low rectal resection and anastomosis, for cervical carcinoma, evaluation, 31, 262

Fallopian tubes localization of primary adenocarcinoma, report on 33 cases, 30, 183 Ferritin and other tumor markers, combination assay in serum for ovarian cancer, 29, 66 o~-Fetoprotein producing endometrial adenocarcinoma, case report, 29, 370 subfraction, production by ovarian endodermal sinus tumor cell line, 25,281; letter to editor, 31, 367 Fistula vagino-peritoneal, at cervical carcinoma presentation, case report, 31, 352 Flow cytometry DNA, as prognostic indicator in ovarian cancer, analysis. 29, 176 5-Fluorouracil continuous infusion, and bolus cis-platinum, for metastatic and recurrent squamous cell carcinoma of cervix, evaluation, 29. 76 and 5-fluorouracil-deoxyribose, alone or in combination with other drugs, continuous infusion as salvage therapy in advanced ovarian carcinoma, 29, 348

Genital tract female, correlation of histology with human papillomavirus DNA detection, 31, 176 Gestational choriocarcinoma cerebral metastatic, with primary neurological presentation, case report, 29, 361 high-risk, EMA/CO regimen, 31,439 and hydatidiform mole and normal placenta, trophoblast cells, cross-reactivity with monoclonal antibodies to lymphocyte markers, 29, 94 late brain recurrence, case report, 31, 467 Gestational trophoblastic disease high-risk metastatic, analysis of treatment failure, 29, 199

placental site trophoblastic tumor, clinical characteristics, 31, 32 post-molar nonmetastatic, and molar pregnancies, human chorJonic gonadotropin regression rates, comparison, 29, 82 repeat, term pregnancy after three events, case report, 29, 2 5 5 Gestational trophoblastic tumor, s e e Gestational choriocarcinoma Gliomatosis peritonei with endometriosis externa, case report, 29, 263 Gonadotropins human chorionic, s e e Human chorionic gonadotropin urinary fragments as markers in gynecologic cancers initial serial studies, 31, 91 sensitivity and specificity, comparison with other markers, 31.82; discussion, 31, 101 Granulomatous disease disseminated, bacillus Calmette-Gudrin-induced, rapid onset after chemoimmunotherapy for ovarian carcinoma, 31, 321 Gynecologic cancers urinary gonadotropin fragments as markers initial serial studies, 31, 91 sensitivity and specificity, comparison with other markers, 31, 82; discussion, 31, 101

H Heart metastasis of endometrial adenocarcinoma malignant pericardial effusion, case report, 29, 234 right ventricular, case report, 29, 231 Hernia sac umbilical, extragonadal sex cord tumor with annular tubules, implications for histogenesis, 30, 71 Herpes simplex virus antigens, search for presence in specimens of Paget's disease of vulva, 31, 384 Hexamethylmelamine. s e e Altretamine Histiocytoma malignant fibrous, of pelvis, case report, 30, 285 Histology correlation with human papillomavirus DNA detection in female genital tract, 31, 176 second-!ook specimen in advanced ovarian cancer, clinical relevance, 29, 58 HIV, s e e Human immunodeficiency virus

SUBJECT INDEX Hormonal therapy sequential cyclical, in endometrial cancer, efficacy and correlation with steroid receptor status, 31, 327 Human chorionic gonadotropin serum levels in pure ovarian dysgerminoma, analysis, 30, 44 fi subunit, regression in molar pregnancies and post-molar nonmetastatic gestational trophoblastic neoplasia, comparison, 29, 82 urinary free /~-subunit and core fragment as markers in gynecologic cancers initial serial studies, 31, 91 sensitivity and specificity, comparison with other markers, 31, 82; discussion, 31, 101 Human immunodeficiency virus positive status, association with positive Papanicolaou screening: identification of highrisk population, 31, 184; discussion, 31, 189 Hybridization sandwich and in situ techniques, in screening of premalignant cervical lesions for human papillomavirus type 16 DNA, comparison, 30. 251 Hydatidiform mole adolescent, treatment and sequelae. 30, 196 complete, increased frequency in women with repeated spontaneous abortion, 31, 310 and gestational choriocarcinoma and normal placenta, trophoblast cells, cross-reactivity with monoclonal antibodies to lymphocyte markers, 29, 94 persistent trophoblastic disease development in course of, identification of prognostic factors, 30, 57 Hypercalcemia associated squamous carcinoma arising in dermoid cysts, clinicopathologic case studies, 29, 222 Hyperplasia endometrium, associated epithelial mucin secretion pattern, analysis, 30, 274 Hypomagnesemia with seizures, cisplatin-induced, case report and literature review, 30, 104 Hysterectomy radical abdominal, associated ureteral damage, prevention by peritoneal sheathing of ureters or retroperitoneal suction drainage, comparison, 30, 222 with bilateral pelvic lymphadenectomy, in

493

cervical carcinoma, associated surgical specimens, analysis of uterine body invasion, 30, 173 subsequent recurrent cervical carcinoma, clinical nature, 30, 381 Wertheim, in geriatric population for primary treatment of cervical carcinoma, evaluation, 31, 227

Immune responses as indicator of clinical status in malignant cervical neoplasia, multiparameter analysis, 31, 409 Immunohistochemistry amylase-producing CAl9-9-positive ovarian mucinous cystadenocarcinoma, 30, 372 Infection bacillus Calmette-Gu6rin, disseminated, rapid onset after chemoimmunotherapy for ovarian carcinoma, 31, 321 Influenza A virus infected ovarian carcinoma cell lines, lysates from, in treatment of advanced ovarian cancer, 29, 337 Intestine small, absorbable synthetic mesh sling for. in reduction of radiation-induced injury in pelvic malignancies, 29, 283 Irradiation, see also Radiotherapy abdominopelvic, after reexploration for ovarian carcinoma, evaluation, 31, 396 induced small-bowel injury in pelvic malignancies, reduction with absorbable synthetic mesh intestinal sling. 29, 283 inguinal lymph node, postoperative, with electrosurgery in vulvar carcinoma, analysis, 29, 158 para-aortic node, in treatment of cervical cancer, evaluation, 31. 371 pelvic postoperative, for Stage ll ovarian carcinoma, 20-year review, 29, 26 whole-abdominal, epithelial ovarian carcinoma patients, determinants of survival, 30, 201

Lactic dehydrogenase serum levels, analysis in pure ovarian dysgerminoma, 30, 44 Laparotomy reexploratory for ovarian carcinoma, subsequent

494

su~JECX INDEX

abdominopelvic irradiation, evaluation, 31, 396 second-look in ovarian cancer comparison of findings with preoperative computed tomography, 29. 37 routine, evaluation of justification, 31,249 Stages IIB-IV, microscopical features of specimens, clinical relevance, 29, 58 subsequent lymphoceles development, case report, 29, 382 positive findings of ovarian carcinoma, evaluation of subsequent treatment and survival, 31, 9; discussion, 31, 22; response, 31, 24 after primary chemotherapy for nondysgerminomatous germ cell malignancies of ovary, evaluation, 31, 268 in Stages III and IV ovarian carcinoma, subsequent recurrent disease. 29, 274 or third, with chemotherapy, subsequent minimal residual epithelial ovarian carcinoma. treatment with whole-abdomen radiation, 29, 168 Leg recurrent acute cellulitis, occurrence in patients after radical vulvectomy, 29, 50 Lesions central nervous system, association with advanced ovarian cancer, evaluation, 30, 87 neoplastic, uterine cervix, distribution of cervical carcinoma antigen and comparison with other tumor markers, 30, 63 premalignant cervical, screening for human papiIlomavirus type 16 DNA by sandwich and in situ hybridization techniques, comparison, 30, 251 Leukocytosis inducing ovarian anaplastic carcinoma cell line, establishment and characterization. 30, 35 Lymphadenectomy bilateral pelvic, with radical hysterectomy in cervical carcinoma, associated surgical specimens, analysis of uterine body invasion, 30, 173 Lymph nodes inguinal metastasis of basal cell carcinoma of vulva, case report, 29, 113 postoperative irradiation, with electrosurgery in vulvar carcinoma, analysis, 29, 158 metastases, in Stage IB cervical carcinoma, clinical factors affecting survival, review, 31, 389 para-aortic, irradiation in treatment of cervical

cancer, evaluation, 31, 371 pelvic and para-aortic, metastases in untreated primary cervical carcinoma, presurgical evaluation by computerized tomography, predictive value, 30, 209 retroperitoneal, metastatic epithelial ovarian cancer, association with elevated serum CA125, case report, 29. 356; letter to editor, 31, 365; reply, 31, 366 Lymphoceles after second-look laparotomy for ovarian cancer, case report, 29, 382 Lymphocysts pelvic, after radical surgery for cervical cancer, 10-year experience, 29, 333 Lymphography bipedal, in initial evaluation of endometrial carcinoma, applicability, 31. 276 Lymphoma Burkitt's-like. presenting as gynecologic tumor, case report. 30, 131 primary aneuploid, of uterine cervix, case report, 30, 302

M

Malignancies extraovarian endometriosis, case reports and literature review, 30, 123 gynecological, CA15-3 as tumor marker in, analysis, 30, 265 low potential in presumed Stage I or II ovarian tumors, evaluation of surgical staging in, 31, 402 nondysgerminomatous germ cell, of ovary, primary chemotherapy and role of secondlook laparotomy, 31, 268 pelvic, associated radiation-induced small-bowel injury, reduction with absorbable synthetic mesh intestinal sling, 29, 283 Mammography and physical exam. age-related significance of findings in relation to breast cancer detection, 31, 166; discussion, 31, 173; response, 31, 175 Medroxyprogesterone acetate with tamoxifen growth regulation of endometrial carcinoma cells in vitro, 30, 239 in sequential cyclical hormonal therapy in endometrial cancer, efficacy and correlation with steroid receptor status, 31, 327 Melanosis cervical, case report, 29, 101

SUBJECT INDEX Merkel cell carcinoma vulva, case report. 29, 105 Mesh synthetic, s e e Synthetic mesh Metastases cardiac endometrial adenocarcinoma: malignant pericardial effusion, case report, 29, 234 right ventricular, endometrial carcinoma, case report, 29, 231 central nervous system, in advanced ovarian carcinoma, evaluation, 30, 398 cerebral, choriocarcinoma: primary neurological presentation, case report, 29, 361 gastrointestinal tumors, and primary ovarian tumors, carcinoembryonic antigen detection, 30, 407 late, gestational choriocarcinoma to brain, case report, 31, 467 lymph node inguinal, of basal cell carcinoma of vulva, case report, 29, 113 retroperitoneal, of epithelial ovarian cancer, association with elevated serum CA125, case report, 29, 356; letter to editor, 31, 365; reply, 31, 366 in Stage IB cervical carcinoma, clinical factors affecting survival, review, 31, 389 and primary tumors, ovarian, variations in steroid receptor levels, 31, 424 squamous cell carcinoma of cervix, management of associated malignant pericardial effusion, case report, 31, 338 Methotrexate with thio-TEPA and vincristine, as chemotherapy regimen for ovarian cancer, case studies over 10-year period, 31,285 Microscopy immunoelectron, amylase-producing CA19-9positive ovarian mucinous cystadenocarcinoma, 30, 372 Mitomycin with vincristine, bleomycin, and cisplatin, phase II trial as neoadjuvant therapy in high-risk cervical carcinoma, 30, 1 Mole hydatidiform, s e e Hydatidiform mole Morphometry comparative, in analysis of depth of invasion in vulvar carcinoma, 29, 12 and DNA flow cytornetry, as prognostic indicators in advanced ovarian cancer, analysis, 29, 176 Mucins epithelial, secretion pattern in normal, hyper-

495

plastic, and adenocarcinomatous endometrium, 30, 274

Neoplasia cervical, distribution of cervical carcinoma antigen and comparison with other tumor markers, 30, 63 cervical intraepithelial differentiation from human papillomavirus, role of colposcopy, 27, 197; letter to editor, 29, 120; reply, 29, 121 and invasive, risk, relationship to dietary vitamin A, 30, 187 treatment with cryosurgery, retrospective evaluation, 30, 21 genital, identification of high-risk population: relationship between HIV status and positive Pap smear tests, 31, 184; discussion, 31. 189 gestational trophoblastic, s e e Gestational trophoblastic disease vulvar dermatofibrosarcoma protuberans, case report, 30, 149 vulvar intraepithelial, unrecognized invasive carcinoma in, evaluation, 31, 154; discussion, 31, 163; response, 31, 165 The Netherlands Nijmegen region, cervical cancer population screening 1976-1985, 30, 388 survival 1970-1985, evaluation, 30, 51 Neuroendocrine carcinoma vulva, case report, 29, 105 Neurological symptoms as primary presentation of metastatic cerebral choriocarcinoma, case report, 29, 361 Neuropathies associated with radical pelvic surgery for gynecologic cancer, case reports, 31, 462 O Ohkawa technique in prevention of ureteral damage after radical abdominal hysterectomy, comparison with retroperitoneal pelvic suction drainage, 30. 222 Oncolysates ovarian viral, in treatment of advanced ovarian cancer, 29, 337 Ovarian adenocarcinoma advanced, combination and single-agent chemosensitivity prediction in, concordance

496

SUBJECT INDEX

with murine subrenal capsule xenograft assay, 30, 416 associated CA125 in tumor tissue and serum, determination, 30, 342 invasive, monitoring by serum CA125 and lipidassociated sialic acid levels, comparison, 30, 98 Ovarian cancer advanced, various microscopical features of second-look specimen, clinical relevance, 29, 58 epithelial advanced, methotrexate-thio-TEPA-vincristine chemotherapy regime, case studies over 10-year period, 31, 285 microscopic, treatment with iv and ip cisplatin, comparison in murine model, 31,50 routine second-look laparotomy, evaluation of justification, 31, 249 second-look laparotomy with preoperative computed tomography, comparison of findings, 29, 37 tumor markers CA125, tissue polypeptide antigen, immunosuppressive acid protein, carcinoembryonic antigen, and ferritin in serum, combination assay, 29, 66 tumor mass and clinical outcome, assessment with serial D-dimer levels, 29, 188 Ovarian carcinoma abdominopelvic irradiation following reexploration, evaluation, 31, 396 adenosquamous, involvement of spleen, case report, 30. 143 advanced associated adnexal tumors, epidermal growth factor receptors in, occurrence and prognostic value, 29, 147 associated central nervous system lesions, evaluation, 30, 87 with central nervous system relapse, evaluation, 30, 398 cisplatin and VP-16-213 treatment, evaluation, 30, 159 clinical variables associated with prognosis, 30, 347 continuous-infusion fluoropyrimidines as salvage therapy, 29, 348 dubulking surgery with Cavitron ultrasonic surgical aspirator, preliminary report, 31. 223 interval reassessment operations during chemotherapy. 30, 359 prognostic DNA flow cytometry and morphometry, analysis, 29, 176 survival after chemotherapy, relationship to

dose level and treatment intensity, 31,233; discussion, 31. 246 treatment with viral oncolysates, evaluation, 29, 337 all histological types, management, role of CA125, 30, 26 anaplastic cell line HTBOA, establishment and characterization, 30, 35 associated malignant pericardial effusion, treatment by systemic chemotherapy, case report, 30, 298 chemoimmunotherapy including bacillus CaP mette-Gu6rin, subsequent disseminated granulomatous disease, 31. 321 early-stage, preoperative serum CA125 levels, initial analysis, 30, 7 established human cell lines, plasminogen activator secretion in vitro, 31, 103 lymphoceles development after second-look laparotomy, case report, 29, 382 metastatic to retroperitoneal lymph nodes, association with elevated serum CA125, case report, 29, 356; letter to editor, 31, 365; reply, 31, 366 patients with multiple previous intraabdominal procedures for. complications of Tenckhoff catheter implantation. 29, 43 persistent, salvage treatment following chemotherapy by hyperfractionation of wholeabdominal radiotherapy, 31, 122; discussion, 31, 135 plasma estradiol levels, analysis, 30, 313 positive second-look laparotomy, evaluation of subsequent treatment and survival, 31, 9: discussion, 31, 22; response, 31, 24 prechemotherapy CA125 serum half-life during induction therapy, prognostic value. 30, 307 radiotherapy salvage, following chemotherapy, evaluation, 30, 15; erratum, 31, 369 whole-abdominal after cytoreductive surgery and chemotherapy, evaluation, 31, 113; discussion, 31, 121 survival determinants, 30, 201 serum o~-acid glycoprotein levels, analysis in patients receiving chemotherapy, 29, 305 small-cell, aggressive epithelial cancer in young patients, case report, 29, 365 squamous cell arising in dermoid cysts and associated with hypercalcemia, clinicopathologic case studies, 29, 222 pure primary, case report, 29, 257

SUBJECT INDEX Stage II, pelvic irradiation, 20-year review, 29, 26 Stage III, minimal residual after surgical resection and maximal first-line chemotherapy, whole-abdomen radiation for, 29, 168 Stages III and IV negative second-look laparotomy, subsequent recurrence, 29, 274 treatment with adriamycin plus cisplatin, evaluation, 29. 208 Ovarian cystadenocarcinoma mucinous amylase-producing CAl9-9-positive, immunohistochemical and immunoelectron microscopic study, 30, 372 with low malignant potential, association with mature cystic teratoma, case report, 29, 250 Ovarian plasmacytoma case report, 29, 378 Ovarian teratoma immature grade 3, adjuvant chemotherapy for, normal pregnancy and delivery two years after, 29, 245 treatment results, 30, 321 Ovary dermoid cysts, derived squamous carcinoma associated with hypercalcemia, clinicopathologic case studies, 29, 222 endodermal sinus tumor association with ataxia-telangiectasia, case report, 29, 240 cell line producing specific type of c~-fetoprotein, establishment and characterization. 25, 281; letter to editor, 31, 367 low-malignant-potential tumors, primary staging, 31,402 malignant tumors, preservation of ovarian function and reproductive ability in patients, 30, 329 nondysgerminomatous germ cell malignancies, primary chemotherapy and role of secondlook laparotomy, 31, 268 primary and metastatic tumors, detection of carcinoembryonic antigen, 30, 407 pure dysgerminoma, serum lactic dehydrogenase, alkaline phosphatase, and human chorionic gonadotropin levels, analysis, 30, 44 sclerosing stromal tumors, associated with endometrial adenocarcinoma, case report, 29, 392 tumor steroid receptor levels, variation within

497

primary tumors and between primary tumors and metastases, 31, 424

Paget's disease vulva, specimen analysis for herpes simplex virus antigens and human papillomavirus antigen and DNA, 31, 384 Papillomavirus human antigen and DNA, search for presence in specimens of Paget's disease of vulva, 31, 384 differentiation from cervical intraepithelial neoplasia, role of colposcopy, 27, 197; letter to editor, 29, 120; reply, 29, 121 DNA, detection in female genital tract, correlation with histology, 31, 176 type of, prognostic significance in cervical cancer, 29, 267 type 16, DNA in premalignant cervical lesions, screening by sandwich and in situ hybridization techniques, comparison, 30, 251 Pap smear abnormal, association with H1V status: identification of high-risk population, 31, 184; discussion, 31, 189 Paraovarian cystadenocarcinoma with low malignant potential, case report, 30, 216 Pelvis exenteration anterior, role in treatment of recurrent cervical cancer, 31, 205: discussion, 31, 214; response, 31, 216 total, with low rectal resection and anastomosis, for cervical carcinoma, evaluation, 31, 262 lymphocysts, occurrence after radical surgery for cervical cancer, 10-year experience, 29, 333 malignancies associated radiation-induced small-bowel injury, reduction with absorbable synthetic mesh intestinal sling, 29, 283 chemosensitivity testing with ATP-bioluminescence assay, 31, 191 extragenital mixed mi~llerian, case report, 30, 422 malignant fibrous histiocytoma, case report, 30, 285 postoperative irradiation for Stage II ovarian carcinoma, 20-year review, 29, 26

498

SUBJECT INDEX

radical surgery for gynecologic cancer, associated neuropathies, case reports, 31,462 Pericardium malignant effusion in ovarian carcinoma, treatment by systemic chemotherapy, case report, 30, 298 secondary to cervical carcinoma metastasis, management, case report, 31. 338 Peritoneal cavity fistula to vagina, at cervical carcinoma presentation, case report, 31, 352 Peritoneal fluid in patients with endometrial carcinoma, cytology, prognostic significance, 30, 76 Peritoneum and intraperitoneal cavity, microscopic ovarian cancer, treatment with with iv and ip cisplatin in murine model, comparison. 31, 50 pelvic, papillary adenocarcinoma, clinical features and treatment results, 31, 315 Physical examination and mammography, age-related significance of findings in relation to breast cancer detection, 31, 166; discussion, 31, 173: response, 31, 175 Placenta normal, and hydatidiform mole and gestational choriocarcinoma, trophoblast cells, crossreactivity with monoclonal antibodies to lymphocyte markers, 29. 94 Plasma, s e e a l s o Serum CA125 and lipid-associated sialic acid levels as markers for gynecologic cancers, comparison with urinary gonadotropin fragments initial serial studies, 31, 91 sensitivity and specificity, 31, 82; discussion, 31, 101 estradiol levels, analysis in epithelial ovarian carcinoma patients, 30, 313 Plasmacytoma ovary, case report, 29, 378 Plasminogen activators secretion by established lines of human ovarian carcinoma cells in vitro, 31, 103 c i s - P l a t i n u m , s e e Cisplatin Population screening cervical cancer in region of Nijmegen, The Netherlands 1976-1985, 30, 388 Pregnancy and delivery, normal, 2 years after adjuvant chemotherapy for grade 3 immature ovarian teratoma, 29, 245 molar adolescent, treatment and sequelae, 30, 196

and post-molar nonmetastatic gestational trophoblastic neoplasia, human chorionic gonadotropin regression rates, comparison, 29, 82 second trimester, diagnosis of cervical carcinoma in, associated management problems, 30. 120 term, after three trophoblastic disease events, case report, 29, 255 Presidential address 18th annual meeting: Society of Gynecologic Oncologists--Present and Future, 30, 153 Prognosis in advanced ovarian carcinoma associated clinical variables, 30, 347 value of DNA flow cytometry and morphometry. 29, 176 epidermal growth factor receptors in adnexal tumors, 29, 147 in cervical adenocarcinoma, prognostic features, analysis, 31, 137; discussion, 31, 149; response, 31, 152 in cervical carcinoma, significance of endometrial extension, 31, 301 type of human papillomavirus. 29, 267 development of persistent trophoblastic disease in course of hydatidiform mole, associated factors, 30, 57 in early vulvar cancer, histomorphologic factors, 31, 43 in endometrial cancer, cytosolic estrogen and progestin receptor levels as indicators, analysis, 31, 65; discussion, 31, 78: response, 31, 81 in ovarian carcinoma serial D-dimer levels in, 29, 188 value of CA125 serum half-life during induction therapy, 30, 307 Proteins immunosuppressive acid, and other tumor markers, combination assay in serum for ovarian cancer, 29, 66 Provera, s e e Medroxyprogesterone acetate

Radiotherapy, s e e a l s o Irradiation for cervical cancer, bladder and rectal complications, 29, 1 salvage, for ovarian carcinoma following chemotherapy, evaluation, 30, 15; e r r a t u m , 31,369 whole-abdominal following cytoreductive surgery and che-

SUBJECT INDEX motherapy in ovarian carcinoma, evaluation, 31, 113; discussion, 31, 121 hyperfractionation, salvage treatment of persistent ovarian carcinoma following chemotherapy, 31, 122; discussion, 31. 135 for minimal residual epithelial ovarian carcinoma after surgical resection and maximal first-line chemotherapy, evaluation. 29, 168 whole abdominopelvic, after chemotherapy for ovarian carcinoma, evaluation, 30, 15 Rectum complications following radiotherapy for cervical cancer, 29, 1 low resection and anastomosis at time of pelvic exenteration for cervical carcinoma, evaluation, 31,262 Reproduction capability, and ovarian function, preservation in patients with malignant ovarian tumors, 30, 329 Resection and anastomosis, low rectal, at time of pelvic exenteration for cervical carcinoma, evaluation. 31, 262 Retroperitoneum lymph nodes, metastatic epithelial ovarian cancer, association with elevated serum CA125, case report. 29, 356; letter to editor. 31, 365; reply, 31, 366 ureteral placement and suction drainage for prevention of ureteral damage after radical abdominal hysterectomy, comparison with peritoneal sheathing of ureters. 30, 222 Risk factors repeated spontaneous abortion, association with increased frequency of complete hydatidiform mole. 31. 310 Rupture uterus, secondary to malignant mixed mesodermal tumor, case report, 30, 137 $ Salvage therapy for ovarian carcinoma after positive secondlook laparotomy, evaluation, 31, 9; discussion. 31, 22; response, 31, 24 Sarcoma botryoides uterine cervix, in young women, clinicopathological study of 13 cases, 29, 290 Seizures in cisplatin-induced hypomagnesemia, case report and literature review, 30, 104 Serum, s e e a l s o Plasma al-acid glycoprotein levels, analysis in epithelial

499

ovarian cancer patients receiving chemotherapy, 29, 305 CA125 half-life during induction therapy for ovarian cancer, prognostic value, 30, 307 CA125 levels elevated, association with epithelial ovarian cancer metastatic to retroperitoneal lymph nodes, case report, 29, 356; letter to editor, 31, 365; reply, 31, 366 and lipid-associated sialic acid levels, in monitoring patients with invasive ovarian adenocarcinoma, comparison. 30, 98 in ovarian adenocarcinoma patients, determination, 30, 342 preoperative, in early-stage ovarian carcinoma patients, initial analysis. 30.7 and tissue polypeptide antigen, immunosuppressive acid protein, carcinoembryonic antigen, and ferritin levels, as markers for ovarian cancer, combination assay. 29, 66 D-dimer serial levels in ovarian cancer patients. in assessment of tumor mass and clinical outcome, 29, 188 human chorionic gonadotropin /3 subunit. regression in molar pregnancies and postmolar nonmetastatic gestational trophoblastic neoplasia, comparison. 29, 82 lactic dehydrogenase, alkaline phosphatase, and human chorionic gonadotropin levels, analysis in pure ovarian dysgerminoma, 30. 44 Sex cords associated tumor with annular tubules, extragonadal presentation in umbilical hernia sac: implications' for histogenesis, 30, 71 Sheathing peritoneal, ureters in prevention of ureteral damage after radical abdominal hysterectomy. comparison with retroperitoneal pelvic suction drainage, 30. 222 Sialic acid lipid-associated and CA125. serum levels in monitoring patients with invasive ovarian adenocarcinoma, comparison, 30.98 plasma, as marker for gynecologic cancers. comparison with urinary gonadotropin fragments correlation with changing clinical status, 31, 91 sensitivity and specificity, 31, 82; discussion, 31, 101 Sling intestinal, absorbable synthetic mesh. in re-

500

SUBJECT INDEX

duction of radiation-induced small-bowel injury in pelvic malignancies, 29, 283 Society of Gynecologic Oncologists Gynecologic Oncology--Preparing for the Third Decade: presidential address at 19th annual meeting, 31, 1 Present and Future: presidential address at 18th annual meeting, 30, 153 Spleen involvement in ovarian adenosquamous carcinoma, case report, 30, 143 Staging postoperative, cervical carcinoma, importance of uterine body invasion, 30, 173 primary surgical, ovarian tumors of low malignant potential, 31, 402 Steroid receptors cytosolic levels in endometrial cancer, evaluation as predictor of survival, 31, 65; discussion, 31, 78; response, 31, 81 levels in ovarian tumors, variation within primary tumors and between primary tumors and metastases, 31, 424 tumor tissue, in endometrial cancer, correlation with efficacy of sequential cyclical hormonal therapy, 31, 327 Subrenal capsule xenograft assay ovarian adenocarcinoma tumors for combination and single-agent sensitivity, associated predictions, concordance with therapy results, 30, 416 Suction retroperitoneal pelvic, for prevention of ureteral damage after radical abdominal hysterectomy, comparison with peritoneal sheathing of ureters, 30, 222 Surgery cytoreductive, with chemotherapy in ovarian carcinoma, evaluation of subsequent wholeabdominal radiotherapy, 31, 113; discussion, 31, 121 debulking, for ovarian cancer, use of Cavitron ultrasonic surgical aspirator, preliminary report, 31, 223 interval reassessment, during chemotherapy in treatment of advanced ovarian carcinoma, evaluation, 30, 359 intraabdominal, multiple previous procedures in ovarian carcinoma patients, associated complications of Tenckhoff catheter implantation, 29, 43 in patients with malignant ovarian tumors, preservation of ovarian function and reproductive ability, 30, 329 radical for cervical cancer Stages IB, IIA, and lIB

with bulky tumor, preoperative adjuvant chemotherapy in, 29, 321 pelvic, for gynecologic cancer, associated neuropathies, case reports, 31, 462 Survival cervical cancer in Nijmegen region, The Netherlands, 1970-1985, evaluation, 30, 51 cervical carcinoma in patients 35 years or younger, comparison with treatment modality, 31, 430 Stage 1B, with lymph node metastases, clinical factors, review, 31, 389 endometrial cancer, as function of cytosolic estrogen and progestin receptor levels, analysis, 31, 65; discussion, 31, 78; response, 31, 81 ovarian carcinoma after chemotherapy, relationship to dose level and treatment intensity, 31,233; discussion, 31, 246 after positive second-look laparotomy, evaluation, 31, 9; discussion, 31, 22; response, 31, 24 after whole-abdomen irradiation, determinants, 30, 201 Synthetic mesh absorbable, in creation of intestinal sling to reduce small-bowel radiation-induced injury in pelvic malignancies, 29, 283

Tamoxifen effect on cervical cancer cell lines Caski, HeLa, and ME-180 hi vitro, 30, 228 and medroxyprogesterone acetate growth regulation of endometrial carcinoma cells in vitro, 30, 239 in sequential cyclical hormonal therapy in endometrial cancer, efficacy and correlation with steroid receptor status, 31, 327 Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma, complications, 29, 43 Teratoma mature cystic, see Dermoid cyst ovary, immature grade 3, adjuvant chemotherapy for, normal pregnancy and delivery two years after, 29, 245 treatment results, 30, 321 Therapy neoadjuvant, in high-risk cervical carcinoma: phase II trial of mitomycin, vincristine, bleomycin, and cisplatin, 30, 1

SUBJECT INDEX salvage, continuous-infusion fluoropyrimidines, in treatment of advanced ovarian carcinoma, 29, 348 Thio-TEPA, s e e Triethylenethiophosphoramide Tomography computerized, s e e Computerized tomography Transferrin receptors identification in cervical and endometrial tissues, 31, 292 Triethylenethiophosphoramide with methotrexate and vincristine, as chemotherapy regimen for ovarian cancer, case studies over 10-year period, 31, 285 Trophoblast cells normal placenta, hydatidiform mole, and gestational choriocarcinoma, cross-reactivity with monoclonal antibodies to lymphocyte markers, 29, 94 Trophoblastic disease gestational, s e e Gestational trophoblastic disease persistent, development in course of hydatidiform mole, identification of prognostic factors, 30, 57 Tumor angiogenesis factor associated activity of gynecologic tumor cell lines on chorioallantoic membrane (chicken embryo), 29, 87 Tumor markers D-dimer, in serum of ovarian cancer patients, serial levels in assessment of tumor mass and clinical outcome, 29, 188 in gynecological malignancies, CA15-3 potential applicability, 30, 265 Tumor mass bulky, cervical cancer Stages IB, IIA, and lIB, preoperative adjuvant chemotherapy in treatment, 29, 321 in ovarian cancer, assessment with serial Ddimer levels, 29, 188 Tumors adnexal, in advanced ovarian carcinomas, epidermal growth factor receptors in, occurrence and prognostic value, 29, 147 endodermal sinus ovarian association with ataxia-telangiectasia, case report, 29, 240 cell line producing specific type of a-fetoprotein, establishment and characterization, 25,281; letter to editor, 31,367 primary endometrial, successful treatment, case report, 31, 357 gestational trophoblastic, high-risk, EMA/CO regimen, 31, 439 gynecologic cell lines planted on chorioallantoic mem-

501

brane, tumor angiogenic activity (chicken embryo), 29, 87 presentation of Burkitt's-like lymphoma as, case report, 30, 131 mixed mesodermal malignant, resulting uterine rupture, case report, 30, 137 mixed mtillerian malignant extragenital, preceded by ovarian serous papillary carcinoma, case report, 30, 422 uterine, case report and literature review, 30, 291 ovarian adenocarcinoma, CA125 determination in tissue, 30, 342 with low malignant potential, primary staging, 31, 402 malignant, preservation of ovarian function and reproductive ability in patients, 30, 329 primary and metastatic, detection of carcinoembryonic antigen, 30, 407 sclerosing stromal, associated with endometrial adenocarcinoma, case report, 29, 392 steroid receptor levels, variation within primary tumors and between primary tumors and metastases, 31, 424 paraovarian cystadenocarcinoma of low malignant potential, case report, 30, 216 pelvic, chemosensitivity testing with ATP-bioluminescence assay, 31, 191 placental site trophoblastic, clinical characteristics, 31, 32 sex cord with annular tubules, extragonadal presentation in umbilical hernia sac: implications for histogenesis, 30, 71

U Ultrasonic surgical aspirator Cavitron, s e e Cavitron ultrasonic surgical aspirator Umbilicus hernia sac, extragonadal sex cord tumor with annular tubules, unique presentation with implications for histogenesis, 30, 71 Ureter involvement of malignant endometriosis, case reports and literature review, 30, 123 peritoneal sheathing in prevention of ureteral damage after radical abdominal hysterectomy, comparison with retroperitoneal pelvic suction drainage, 30, 222

502

SUBJECT INDEX

Urinary bladder complications following radiotherapy for cervical cancer, 29, 1 Urine gonadotropin fragments, as markers in gynecologic cancers initial serial studies, 31, 91 sensitivity and specificity, comparison with other markers, 31, 82; discussion, 31. 101 Uterine body invasion of carcinoma of uterine cervix into, analysis of surgical specimens, 30, 173 Uterus cervix, s e e Cervix miillerian adenosarcoma, case report and literature review, 30, 291 rupture secondary to malignant mixed mesodermal tumor, case report, 30. 137 V Vagina fistula to peritoneal cavity, at cervical carcinoma presentation, case report, 31. 352 Vaginal adenocarcinoma clear cell, Stage II, categorization into substages, evaluation, 31, 56 Vaginal cancer nonsquamous, clinical characteristics and treatment, 29. 309 Vinblastine with Neomycin and cis-platinum, in preoperative adjuvant chemotherapy in treatment of cervical cancer Stages IB, IIA, and I1B with bulky tumor, 29. 321 Vincristine with methotrexate and thio-TEPA, as chemotherapy regimen for ovarian cancer, case studies over 10-year period, 31, 285

with mitomycin, bleomycin, and cisplatin, phase II trial as neoadjuvant therapy in high-risk cervical carcinoma, 30. 1 Vitamin A dietary, relationship to risk of intraepithelial and invasive cervical neoplasia, 30, 187 VP-16-213, s e e Etoposide Vulva dermatofibrosarcoma protuberans, case report, 30, 149 Paget's disease, specimen analysis for herpes simplex virus antigens and human papillomavirus antigen and DNA, 31, 384 Vulval adenocarcinoma clear cell, arising in endometriosis, case report, 29, 385 Vulval carcinoma basal cell, with inguinal lymph node metastases, case report, 29. 113 depth of invasion, comparative morphometric study, 29. 12 early, prognostic factors, 31, 43 electrosurgical operation with postoperative irradiation of inguinal lymph nodes, analysis. 29, 158 invasive, unrecognized in vulvar intraepithelial neoplasia, evaluation, 31. 154; discussion, 31, 163; response, 31. 165 neuroendocrine Merkel cell. case report, 29, 105 verrucous, case report and literature review. 30. 427 Vulval neoplasia intraepithelial, unrecognized invasive carcinoma in, evaluation. 31,154; discussion, 31. 163; response, 31. 165 Vulvectomy radical, associated recurrent acute leg cellulitis, 29. 50